ClinicalTrials.gov recorded primary completion on 4 February 2026 for a Phase 3 China extension study of pembrolizumab in advanced clear cell renal cell carcinoma. The study enrolled 251 participants and evaluated pembrolizumab-based combinations as first-line treatment in Chinese participants.

The registry lists the study as active, not recruiting. Primary completion marks the end of the study’s primary data-collection phase; the supplied record does not report outcome measurements, statistical analyses, or an adverse-event summary.

Background

The trial addressed advanced clear cell renal cell carcinoma, a form of renal cell carcinoma. Its purpose was to evaluate the efficacy and safety of pembrolizumab-containing regimens in Chinese participants receiving first-line treatment. The study also involved belzutifan, quavonlimab, and lenvatinib.

Trial design

This was a Phase 3 China extension study identified as NCT05899049. It enrolled 251 participants with renal cell carcinoma. The registered treatment strategies included pembrolizumab plus belzutifan plus lenvatinib, pembrolizumab/quavonlimab plus lenvatinib, and pembrolizumab plus lenvatinib as the comparator regimen.

The registry describes the study as an evaluation of pembrolizumab plus belzutifan plus lenvatinib, or pembrolizumab/quavonlimab plus lenvatinib, versus pembrolizumab plus lenvatinib. The primary hypotheses included whether pembrolizumab plus belzutifan plus lenvatinib was superior to pembrolizumab plus lenvatinib for progression-free survival and overall survival. The supplied data do not list primary endpoint measurements or results for either hypothesis.

What this means

The primary-completion event indicates that the trial reached the registry milestone for its main study phase. It does not establish whether any pembrolizumab combination improved progression-free survival or overall survival, because no efficacy measurements, confidence intervals, p-values, or comparative analyses were provided in the data.

The available record also does not provide a safety finding. The study status remains active, not recruiting, and the registry entry may continue to be updated as additional trial information becomes available.

Source

Source: ClinicalTrials.gov, study record for NCT05899049, reporting primary completion on 4 February 2026. The registry record is available at clinicaltrials.gov/study/NCT05899049.